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INTRODUCTION 
 The importance of risk factors such as diabetes mellitus (DM), 
hypertension, smoking, family history of premature heart disease, 
dyslipidaemia, male gender and advanced age has been established in 
predicting the risk of cardiovascular disease (CVD) by numerous studies. 
 However, in half of those who develop CVD, the established risk factors 
are largely absent. Identification of additional factors is therefore necessary to 
identify more effectively those at risk of CVD.   
 Over the past decade, identification of novel risk factors and predictors 
for CVD has been an area of major interest in preventive cardiology. Serum 
high sensitivity C-reactive protein hs-CRP, a biomarker of inflammation, has 
been shown to effectively predict the risk of adverse cardiovascular (CV) 
events consistently. Despite its initial role as a marker of vascular 
inflammation, recent research has established the role of CRP in atherogenesis. 
It is involved throughout the evolvement of atheromatous lesions and is 
detectable even in the initial phases of plaque development. 
 The currently available highly sensitive assays may detect serum CRP 
levels below 0.3 mg per liter. These lower range hs-CRP levels, previously 
considered normal, have in fact got the predictive capabilities for adverse CV 
events. It has in fact been found to be the single best predictor of future CV 
events among the conventional and novel risk factor.Its role is  an important 
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adjunct to conventional risk factors was established in 2003 according to 
guidelines from the Centers for Disease Control and Prevention (CDC) and the 
American Heart Association (AHA) Serum hs-CRP levels may aid in 
identifying patients at high risk for a first CV event who might otherwise be 
missed by screening for lipids and other conventional risk factors alone. The 
landmark "Justification for the  Use of statins in Primary prevention: an 
Intervention Trial Evaluating Rosuvastatin" (JUPITER) trial stressed the 
benefits of treating individuals with raised hs-CRP levels (despite normal LDL 
levels) by showing a 44% reduction in cardiovascular (CV) events. This break-
through led to the recent approval by United States Food and Drug 
Administration (FDA) for the primary preventive role of statins in such 
individuals who are at high risk for future CV events. The Gensini scoring 
system is a valuable aid to estimate the severity of CAD according to 
angiographicindings. The calculation is based on the evaluation of number of 
stenotic  segments along with their respective degrees of luminal narrowing 
and localization within the coronary tree. Coronary atherosclerosis is the main 
substrate of adverse coronary events and serum hs-CRP levels may act as an 
indirect measure of its extent within the coronary vasculature. This may prove 
to be an inexpensive screening tool in CV risk assessment. Limited information 
is available regarding the correlation between serum hs-CRP levels and the 
extent and severity of CAD, as assessed by Gensini  score in patients submitted 
to coronary angiography. We carried out a study to assess the correlation 
between plasma hs-CRP levels with severity of coronary atherosclerosis. 
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AIM OF THE STUDY 
1. To correlate the levels of hs-C reactive protein with angiographic 
severity of coronary artery stenosis in patients with IHD admitted 
for CAG in Stanley Medical College. 
2. To correlate the levels of hs-C reactive protein with vessel score. 
3. To correlate the levels of hs C reactive protein with stenosis score. 
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REVIEW OF LITERATURE 
INTRODUCTION TO INFLAMMATION IN ATHEROGENESIS 
 A role for inflammation has become well established over the past 
decade or more in theories describing the atherosclerotic disease process.1,2 
From a pathological viewpoint, all stages, ie, initiation, growth, and 
complication of the atherosclerotic plaque, 3,4 might be considered to be an 
inflammatory response to injury.  
 The major injurious factors that promote atherogenesis - cigarette 
smoking, hypertension, atherogenic lipoproteins, and hyperglycemia are well 
established. These risk factors give rise to a variety of noxious stimuli that elicit 
secretion of both leukocyte soluble adhesion molecules, which facilitate the 
attachment of monocytes to endothelial cells, and chemotactic factors, which 
encourage the monocytes’ migration into the subintimal space.  
 The transformation of monocytes into macrophages and the uptake of 
cholesterol lipoproteins are thought to initiate the fatty streak. Further injurious 
stimuli may continue the attraction and accumulation of macrophages, mast 
cells, and activated T cells within the growing atherosclerotic lesion. Oxidized 
low-density lipoproteins may be one of several factors that contribute to loss of 
smooth muscle cells through apoptosis in the atherosclerotic plaque cap, and 
secretion of metalloproteinases and other connective tissue enzymes by 
activated macrophages may break down collagen, weakening the cap and 
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making it prone to rupture. This disruption of the atherosclerotic plaque then 
exposes the atheronecrotic core to arterial blood, which induces thrombosis. 
 
 Thus, virtually every step in atherogenesis is believed to involve 
cytokines, other bioactive molecules, and cells that are characteristic of 
inflammation.  
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INFLAMMATORY MARKERS IN ATHEROGENESIS. 
                      
  It should be pointed out that this inflammatory cascade may have 
sources other than an atherosclerotic coronary artery, including atherosclerosis 
in other arteries, as well as systemic inflammation (eg, connective tissue 
diseases) and local infections (eg, gingivitis, prostatitis, bronchitis, urinary tract 
infections, gastric inflammation). These systemic inflammations may result in 
elevated levels of inflammatory markers that may be incorrectly attributed to 
atherosclerotic CVD.  
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 Nonetheless, increasing recognition of the inflammatory component of 
atherogenesis provides the biological plausibility for the potential use of 
inflammatory markers as indicators of atherogenesis or as predictors of 
atherosclerotic complications. 
 These pathophysiological insights provide potential targets for 
measurement as a means to identify and monitor the ongoing inflammatory 
process. 
 Potential targets for measurement include proinflammatory risk factors 
such as oxidized low-density lipoproteins, proinflammatory cytokines  
(eg, interleukin-1, tumor necrosis factor- ), adhesion molecules (eg, 
intercellular adhesion molecule-1, selectins), inflammatory stimuli with hepatic 
effects (eg, interleukin-6) or the products of the hepatic stimulation, such as 
SAA,  C-reactive protein (CRP), and a host of other acute-phase reactants. 
 Understanding of the inflammatory cascade allows the consideration of a 
number of inflammatory markers as potentially useful predictors of prevalent or 
incident CVD. Such markers, however, may not be useful in the clinical arena 
unless they possess additional characteristics. These include: (1) the ability to 
standardize the assay and to control the variability of the measurement; (2) 
independence from established risk factors; (3) association with CVD clinical 
end points in observational studies and clinical trials; (4) the presence of 
population norms to guide interpretation of results; (5) ability to improve the 
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overall prediction beyond that of traditional risk factors; (6) generalization of 
results to various population groups; and (7) acceptable cost of the assays. The 
use of the marker is also affected by the type of relationship with CVD (eg, 
linear, nonlinear, dichotomous). These characteristics then can be examined in 
the inflammatory markers currently under consideration. 
Table 1. Assays of Inflammatory Markers for Potential Clinical Use* 
Analyte 
 
Stability 
 
Assay 
Availability
 
World Health 
Organization 
Standards 
Available? 
 
Inter 
Assay 
Precision 
 
Soluble adhesion molecules 
(eg, E-selectin, P-selectin, 
intracellular adhesion 
molecule-1, vascular cell 
adhesion molecule-1) 
Unstable 
(unless 
frozen) 
Limited No CV<15% 
Cytokines (eg,interleukin-1ß, 
6, 8, and -10 and tumor 
necrosis factor - ) 
Unstable 
(unless 
frozen) 
Few Yes  
(Reference ) 
CV<15% 
Acute-phase reactants     
    Fibrinogen Unstable 
(unless 
frozen) 
Many Yes  
(Reference ) 
CV<8% 
    SAA Stable One Yes 
(Reference) 
CV<9% 
    hs-CRP Stable Many Yes  
(Reference ) 
CV<10% 
WBC count Stable Many Yes CV<3% 
 
 
 A sizable number of studies have examined the inflammation–CVD 
association through measurement of a variety of analytes. Only some of these 
assays, however, are currently employable in clinical settings, after 
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consideration of the stability of the analyte, the commercial availability of 
assays, the standardization of those assays to allow comparison of results, and 
the precision of the assays as measured by the coefficient of variation. Table 1 
summarizes the currently available assays for inflammatory markers. Several 
markers are only stable when frozen, which limits their use to research settings. 
Likewise, only the acute-phase reactants (fibrinogen and CRP) and WBC count 
have widely available assays. CRP has a proficiency-testing program from the 
College of American Pathologists. A program to standardize CRP testing is 
underway at the Centers for Disease Control and Prevention. Most of the acute-
phase reactant assays have acceptable coefficients of variation. 
 These comparisons of the various inflammatory markers favor CRP 
from the clinical chemistry perspective. It needs to be emphasized that the 
assays considered in Table 1 were for hs-CRP with acceptable precisions down 
to or below 0.3 mg/L. It is within these lower, previously "normal" ranges that 
the hs-CRP levels seem to have predictive abilities for CVD events. Although 
new assays of other inflammatory markers, with precision, standardization, and 
other characteristics that are superior to those of the current assays, may 
become available, the hs-CRP assay represents the best candidate at this time.  
CRP  AS AN  INFLAMMATORY MARKER 
 C-reactive protein is the prototypic marker of inflammation in humans 
and a member of a highly conserved family of proteins called the pentraxins. It 
comprises 5 noncovalently associated protomers arranged symmetrically 
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around a central pore and has a molecular weight of 118 000 Da5. It is a 
nonglycosylated protein in humans, and its gene has been mapped to 
chromosome 1. To date, in phagocytes, it has been shown to bind Fc  receptor 
(Fc R) I and II, and its function appears to clear apoptotic and necrotic cells 
(opsonophagocytosis).  
 CRP is predominantly synthesized in hepatocytes as an acute-phase 
reactant and is transcriptionally driven by IL-6, with synergistic enhancement 
by IL-1. Some recent data challenge the dogma that CRP is exclusively 
produced by the liver, however, and suggest that it is produced in the 
atherosclerotic lesion (especially by smooth muscle cells and macrophages), the 
kidney, neurons, and alveolar macrophages11,12,13,14. mRNA and protein for CRP 
is expressed in arterial plaque tissue, and both CRP mRNA and protein levels 
are 10-fold higher in plaque compared with the normal artery13. Also, it is 
shown that human aortic endothelial cells (HAECs) synthesize and secrete 
CRP.15  
 The most potent agonist for CRP production from HAECs is the 
combination of IL-1 and IL-6. Thus, synthesis and secretion of CRP by cells in 
the atherosclerotic lesion by paracrine/autocrine loops could result in local 
concentrations of CRP far in excess of plasma concentrations and could 
contribute to proinflammatory, proatherogenic effects. Ouchi et al.16 have 
demonstrated CRP mRNA in human adipose tissue. Adiponectin, an 
adipocytokine, significantly decreases CRP mRNA and protein levels, whereas 
leptin has been shown to enhance CRP synthesis in endothelial cells incubated 
with IL-1 and IL-617. 
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Sources of Variability of Inflammatory Markers 
 Generally, the precision and reproducibility of inflammatory marker 
assays such as the acute-phase reactants have been acceptable (Table1). For 
example, the coefficient of variation of hs-CRP assays is generally <10% from 
the 0.3- to 10-mg/L range. 17  Considerable within-individual variability exists, 
however, for both hs-CRP and fibrinogen. In general, although CRP is an acute-
phase reactant and as such has higher within-subject variability than an 
established risk factor such as serum cholesterol, it also has a broader 
distribution in the population. The final result is that, in a manner similar to 
cholesterol, two separate measurements of hs-CRP are adequate to classify a 
person’s risk level and to account for the increased within-individual 
variablility. The distribution of the logarithm of hs-CRP level is a normal 
distribution, and the nontransformed values are skewed toward the higher 
values, with most populations showing >95% of subjects with hs-CRP values 
of <10 mg/L. There seems to be population-to-population consistency in this, 
though as previously stated, data for racial and ethnic populations are limited 
(eg, NHANES III).  
 Sources of variation of inflammatory markers have been studied to 
varying degrees. There seems to be little seasonal or diurnal variation with hs-
CRP. Several factors have been identified as being associated with increased or 
decreased levels of hs-CRP this list is likely incomplete. For example, body 
weight and the metabolic syndrome are consistently associated with elevated 
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hs-CRP, and weight loss is associated with reduction in hs-CRP levels, with 
some authors suggesting that hs-CRP is merely a marker for obesity and insulin 
resistance. This association of hs-CRP with these conditions is poorly defined 
from a mechanism standpoint, and is possibly due to coassociation with 
prevalent vascular disease. Individuals with evidence of active infection, 
systemic inflammatory processes, or trauma should not be tested until these 
conditions have abated. An hs-CRP level of >10 mg/L, for example, should be 
discarded and repeated in 2 weeks to allow acute inflammations to subside 
before retesting.  
Studies of Use of Inflammatory Markers in Clinical Practice 
 Despite the ability of some inflammatory markers to predict incident or 
recurring events, various analyte characteristics and within-individual variation 
seem to limit the analytes to hs-CRP and possibly fibrinogen. The specific 
clinical settings in which hs-CRP or other factors would be most useful, 
however, need to be defined by careful clinical investigations, including clinical 
trials. Inflammatory markers may have greater potential as a means to augment 
risk assessment in the identification of persons who should be considered for 
lipid-lowering, antiplatelet, or other cardioprotective drug therapies, as well as 
for increased emphasis on therapeutic lifestyle changes. If the patient is already 
targeted for these treatments according to current guidelines (eg, secondary 
prevention), then a level of inflammatory marker is less useful. A better 
potential use may be in those patients at baseline risk for whom an additional 
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risk predictor may provide support for or against additional lifestyle or drug 
therapies. Post hoc analyses from two randomized controlled trials 
(AFCAPS/TexCAPS [Air Force/Texas Coronary Atherosclerosis Prevention 
Study] trial of lovastatin versus placebo18 and the Physicians’ Health Study of 
aspirin versus placebo) both suggest that persons with elevated hs-CRP levels 
have a larger absolute risk reduction in the intervention groups, which supports 
the potential utility of hs-CRP to target patients for primary preventive 
interventions.  
 One potential use for markers that might be considered is that of 
monitoring of the effects of therapy, such as an HMG-CoA reductase inhibitor. 
For example, if the marker does not fall, treatment might be intensified. HMG-
CoA reductase inhibitors do seem to reduce hs-CRP levels, but the response is 
very heterogeneous, with many nonresponders and a few hyper-responders 
contributing to the reduction in mean hs-CRP level. Unfortunately, it is not 
known if the responders with lowered hs-CRP levels have a greater reduction in 
risk than the nonresponders. Conversely, despite recent indications of possible 
increased risk with the use of estrogen in hormone replacement therapy 
(HRT)and the finding that hs-CRP is increased with estrogen use, it is not yet 
possible to conclude that an increased hs-CRP brought about by estrogen use is 
an indicator of increased CVD risk. Thus, a role of these markers in the 
monitoring of therapy has not been established. 
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CRP  AND ENDOTHELIAL CELLS 
 Several studies have shown an inverse relationship between CRP levels 
and endothelial function19,20,21. CRP induces increased expression of ICAM, 
VCAM, E-selectin, and the chemokine MCP-1, resulting in increased adhesion 
of U937 cells (monocytic cell line) to human umbilical vein endothelial cells. A 
critical enzyme in endothelial cells is endothelial nitric oxide synthase (eNOS).  
 CRP uncouples eNOS, resulting in increased superoxide production, 
decreased NO production, and altered eNOS phosphorylation. These effects 
appear to be mediated via the Fc  receptors CD32 and CD64. These data 
further support a role for CRP in mediating endothelial dysfunction. 
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 By virtue of inhibiting eNOS expression and NO release, CRP blocks 
NO-dependent processes.  
 Furthermore, several groups have shown that CRP in vivo impairs 
endothelial vasoreactivity22,23 Bisoendial et al.24 also demonstrated that CRP 
infusion in patients with hypercholesterolemia resulted in marked deterioration 
of endothelial vasoreactivity. 
 CRP-induced PAI-1 appears to occur via activation of Rho kinase and 
the nuclear factor (NF)- B pathway25. CRP inhibits tissue plasminogen 
activator (tPA) activity via generation of proinflammatory cytokines [IL-1β and 
tumor necrosis factor-  (TNF- )]26. These studies provide additional evidence 
that CRP may be a procoagulant, which has implications for atherothrombosis.  
 An important chemokine is IL-8, a powerful trigger of adhesion of 
monocytes to endothelium. CRP induces IL-8 expression in human coronary 
artery endothelial cells (HCAECs) via activation of NF- B27. This was 
confirmed by Wang et al.28, who showed that IL-8 release was induced by CRP 
via upregulation of MEK (mitogen-activated protein kinase or extracellular 
signal-regulated kinase) and extracellular signal-regulated kinase (ERK) 1/2. 
Also, the CD40–CD40 ligand (CD40L) pathway plays an important role in 
plaque stability, and CRP has been shown to upregulate surface expression of 
CD40 and CD40L.  
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 The Du Clos laboratory and others have shown that CRP binds mainly to 
Fc R2 (CD32) on leukocytes29. CRP binds to both CD32 and CD64 on HAECs 
but not CD16, and that CRP mediates its biological effects in EC via these 2 
receptors. Studies have also shown that CRP binds to LOX-1 and may exert 
proatherogenic effects by binding to the receptors for advanced glycation end 
products.  
CRP AND ENDOTHELIAL DYSFUNCTION. 
 There is tremendous interest in a special subtype of progenitor cells 
isolated from peripheral blood and bone marrow of adults, endothelial 
progenitor cells (EPCs), which have the capacity to circulate, proliferate, and 
differentiate into mature endothelial cells. Importantly, the measurement of 
circulating  EPCs is a surrogate marker of endothelial dysfunction and future 
cardiovascular events. Clinical studies suggest that traditional risk factors for 
coronary atherosclerosis are associated with lower levels of circulating 
EPCs30,31. Importantly, a negative correlation between systemic CRP levels and 
circulating EPC number has been reported in patients with unstable angina. 
Also, low levels of EPCs are associated with adverse cardiovascular events. A 
recent article suggests that in mature ECs, CRP appears to stimulate 
angiogenesis and may be a mediator of neovessel formation in the intima of 
vulnerable plaques, thus suggesting different biological effects on EPCs and 
mature ECs32. EPC-induced angiogenesis was dependent on the presence of 
NO, and CRP treatment caused a decrease in eNOS mRNA expression by 
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EPCs. Also, subsequently, CRP was demonstrated to increase oxidative stress 
and induce apoptosis in these EPCs. Thus, CRP may negatively affect EPCs by 
quenching antioxidant defenses and promoting telomerase inactivation.  
 Thus, a large body of evidence from in vitro studies points to a 
proatherogenic, prothrombotic role for CRP in ECs. These effects of CRP may 
result in endothelial dysfunction and impairment of EPC survival and 
differentiation.  
 It is clear that CRP is proatherogenic in monocyte-macrophages since it 
increases tissue factor expression, promotes monocyte chemotaxis and adhesion 
to ECs, reactive oxygen species release, MMP-1, CCR2, cytokines, and  
M-CSF, and promotes OxLDL uptake, thus leading to increased foam cell 
formation. Furthermore, CRP is present in foam cells in the atherosclerotic 
lesion and activates complement. 
 CRP exerts direct proatherosclerotic effects at the level of VSMCs. 
Also, in VSMCs, CRP has been shown to upregulate inducible NO synthase 
(iNOS) and certain cell signal transduction pathways including MAPK pathway 
and NF- B. CRP promotes apoptosis of VSMCs and thus may contribute to 
plaque instability.  
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CRP AS A MARKER OF ENDOTHELIAL DYSFUNCTION 
 However, there have been few studies to compare the relationship of 
various inflammatory biomarkers with vascular inflammation assessed by 
18F-FDG PET. Recently, Rudd et al.33 demonstrated that arterial 18F-FDG 
uptake showed the trends of positive correlation with levels of several 
circulating inflammatory biomarkers including hsCRP. According to Hye Jin 
Yoo et al,34  Compared with individuals with low hsCRP and high LDL-C 
levels (hsCRP < 2 mg/L and LDL-C 130 mg/dL) or low hsCRP and low LDL-
C levels (hsCRP < 2 mg/L and LDL-C < 130 mg/dL), healthy subjects with 
high hsCRP and low LDL-C levels (hsCRP 2 mg/L and LDL-C < 130 mg/dL) 
had increased vascular inflammation, measured using 18F-FDG PET. However, 
no significant differences in IMT were observed. TBR levels measured using 
18F-FDG PET are independently associated with hsCRP levels and diastolic 
blood pressure, whereas IMT values are related to age, diastolic blood pressure, 
and LDL-C levels. Further studies are needed to determine the clinical roles of 
18F-FDG PET and hsCRP in prognostic and therapeutic implications for 
cardiovascular events.  
CRP  AND CLINICAL PROFILE OF CAD 
 
 A meta-analysis of prospective population-based studies has compared 
persons in the lower tertile of hs-CRP with those in the upper tertile.35,36 With a 
good consistency between studies, a relative odds of 2.0 (95% CI 1.6–2.5) for 
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major coronary events was observed for the upper tertile with the lowest tertile 
used as a reference. These prospective studies include men,37,38 women,39,40  and 
the elderly.41-43 Large population-based studies such as the study from the 
MONICA (Monitoring trends and determinants in Cardiovascular disease) 
Augsberg Center in Germany, the Atherosclerosis Risk in Communities 
Study,44 the Women’s Health Study,  the Honolulu Heart Study, and the 
NHANES (National Health And Nutrition Examination Survey) studies (cross-
sectional44-46 are also represented. In general, most studies show a dose-
response relationship between the level of hs-CRP and risk of incident coronary 
disease. It should be noted that studies of other, newer inflammatory markers 
such as interleukin-6 and SAA show similar results A notable characteristic of 
all these studies is their limitation to white North American or European 
populations, with the exception of Japanese-American men in the Honolulu 
Heart Study 47 Data are limited for persons of African, South Asian, or Native 
American descent, who may be at particularly high risk for CVD, and for other 
racial/ethnic groups. Race and ethnicity did not appear to be an effect modifier 
of the hs-CRP–stroke association in one study.  
 The ability of hs-CRP to add to the predictive capacity of other, 
established risk factors has been examined in several studies. Through 
stratification or multivariable statistical adjustment, hs-CRP retains an 
independent association with incident coronary events after adjusting for age, 
total cholesterol, HDL cholesterol, smoking, body mass index, diabetes, history 
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of hypertension, exercise level, and family history of coronary disease. In some 
studies, the magnitude of the relative risk in the upper percentiles of hs-CRP is 
attenuated after this adjustment, including loss of statistical significance. 
Recent studies demonstrate the capability of elevated hs-CRP to predict 
coronary events in women after adjusting for risk factors used in the 
Framingham risk score, and in the elderly with extensive adjustment for CVD 
risk factors and measures of subclinical atherosclerosis. Relatively few studies 
have adjusted for body mass index or for measures of diabetes or glucose 
metabolism.  
 A growing number of studies have examined inflammatory markers as 
predictors of recurrent CVD and death in different settings, including the short-
term risk, long-term risk, and risk after revascularization procedures such as 
percutaneous coronary intervention (PCI), including the risk of restenosis. 
Although several markers have been studied, the strongest association with 
prognosis has been with fibrinogen and hs-CRP. hs-CRP consistently predicts 
new coronary events in patients with unstable angina and acute myocardial 
infarction.48-56 Most of these studies have been long term, but some in-hospital 
survivorship studies 57-60 have also shown an association.  
 For patients with acute coronary syndromes, cutpoints for elevated hs-
CRP different than those for prediction in asymptomatic patients may be useful. 
For example, a level of >10 mg/L in acute coronary syndromes may have better 
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predictive qualities, whereas a level of >3 mg/L may be more useful in patients 
with stable coronary disease.  
 Many analyses have adjusted for other prognostic factors, demonstrating 
continued predictive capacity with hs-CRP. In acute coronary syndromes, hs-
CRP predicts recurrent myocardial infarction independent of troponins, which 
suggests it is not merely a marker for the extent of myocardial damage. Recent 
data also suggest that hs-CRP may be a marker for risk of restenosis after 
PCIs,61,62  but all studies are not in agreement with these results. Elevated hs-
CRP levels also seem to predict prognosis and recurrent events in patients with 
stroke and peripheral arterial disease. These data suggest that hs-CRP may have 
a role in risk stratification of patients with established CVD, although more 
data are needed that compare the prognostic value of elevated levels of hs-CRP 
with other prognostic measures currently in use.  
 The factors that make up the Framingham risk score (age, sex, blood 
pressure, serum total cholesterol or low-density lipoprotein cholesterol level, 
high-density lipoprotein cholesterol level, cigarette smoking, and diabetes) 
account for most of the excess risk for incident coronary heart disease (CHD). 
However, these factors do not explain all of the excess risk, and approximately 
40% of CHD deaths occur in persons with cholesterol levels that are lower than 
the population average. Several lines of evidence have implicated chronic 
inflammation in CHD, and inflammatory markers have received much attention 
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as new or emerging risk factors that could account for some of the unexplained 
variability in CHD risk. 
 In the Framingham risk scoring system, intermediate-risk persons are 
those with a 10% to 20% risk for coronary death or nonfatal myocardial 
infarction (“hard CHD events”) over 10 years. Further stratification by using 
new markers might reclassify some intermediate-risk persons as low-risk (10-
year risk <10%) and others as high-risk (10-year risk >20%). This would 
permit more aggressive risk reduction therapy in persons reclassified as high-
risk and may consequently reduce incident CHD events. Several previous 
meta-analyses 63-65 have assessed the possible independent predictive ability of 
CRP level for incident CHD risk. In 1998, a meta-analysis of 5 long-term, 
population-based prospective cohort studies and 2 cohorts of patients with pre-
existing CHD calculated a risk ratio for coronary events of 1.7 (95% CI, 1.4 to 
2.1) for CRP levels in the top tertile versus the bottom tertile. 
 Although the underlying pathobiology remains under study, the overall 
epidemiological data supporting the association between CRP and adverse 
cardiovascular outcomes are clear. To that end, the CDC and the AHA have 
now recognized the prognostic utility of hs-CRP in a joint statement.66  
 Marc S. Sabatin et al showed  the population which included both 
patients with stable and patients with unstable angina, there were only 75 
coronary events during the 2 years of follow-up, and excess risk was 
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demonstrated only when hs-CRP levels were in the top quintile (>3.6 mg/L), 
with no evidence for a gradient of risk across the lower quintiles.9  
 In contrast, using a large cohort of patients with stable CAD, it was   
able to prospectively apply the CDC/AHA hs-CRP cut points and demonstrate 
that an elevated level of hs-CRP, even >1 mg/L, was associated with an 
increased risk of cardiovascular death, MI, or stroke.  
 The risk was consistent across all the elements of the composite end 
point and remained significant even after adjustment for elements of the 
Framingham Risk Score and other clinical and laboratory parameters. These 
data suggest that among patients with CAD, hs-CRP levels can be used to gain 
fundamental insight into which patients are, despite being asymptomatic at a 
given time and hence deemed clinically stable, in fact pathobiologically 
unstable and at higher risk for adverse cardiovascular events. However, an 
elevated hs-CRP does not appear to identify patients with stable CAD and 
preserved ejection fraction who derive particular benefit from ACE inhibition.  
 From a clinical perspective, the most meaningful measure of CRP's 
value as a marker is its effect on rates of reclassification from intermediate-risk 
to other risk categories. Recent articles have proposed methods of assessing 
clinical risk reclassification when the goal of analysis is risk prediction.  
 Five studies 67,68,69,70,71 included an analysis that compared predictive 
models that used all Framingham risk factors, with and without CRP level, 
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specifically among participants whose 10-year Framingham risk score 
categorized them as intermediate-risk.  
 Using data from the Women's Health Study, Cook and colleagues  
demonstrated that although measures of discrimination did not substantially 
differ between models with and without CRP level, a model that included CRP 
level had better fit, as measured by the Hosmer–Lemeshow calibration statistic. 
In that analysis, 14% of participants originally classified as intermediate-risk 
(10% to 20%) were reclassified as low-risk (<10%) and 5% were reclassified as 
high-risk (>20%). The actual 10-year risk was 19.9% for those reclassified as 
high-risk and 11.5% for those who remained intermediate-risk. 
 The other 4 studies used less rigorous analyses to assess the effect of 
CRP level on risk classification and did not measure calibration, with mixed 
results. Three studies 67,68,70 found that assessing CRP improved risk 
stratification specifically among intermediate-risk participants. 
 In the Monitoring of Trends and Determinants in Cardiovascular 
Disease study 67, assessing CRP level in addition to the Framingham risk 
factors resulted in improved risk classification among participants with an 
initial 10-year risk of 11% to 19%. Among participants with a CRP level 
greater than 3.0 mg/L, some with an initial 10-year risk of 15% to 19% were 
reclassified as high-risk, whereas no participants with an initial 10-year risk of 
11% to 14% were reclassified as high-risk. 
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 In an analysis of data from the Women's Health Study, 68 CRP level was 
clearly predictive of incident cardiovascular disease among participants with 
10-year Framingham risk scores between 10% and 20%. The risk for 
cardiovascular events was twice as high for those with CRP levels between 1.0 
and 3.0 mg/L or between 3.0 and 10.0 mg/L than for those with levels less than 
1.0 mg/L, although CIs were not reported. Similarly, in an analysis from the 
Cardiovascular Health Study, CRP level added to risk prediction among men at 
intermediate risk70. Among men with a 10-year Framingham risk score 
between 10% and 20%, the observed 10-year incidence of CHD was 32% for 
those with CRP levels greater than 3.0 mg/L, compared with between 15% and 
16% for those with CRP levels between 1.0 and 3.0 mg/L or less than 1.0 
mg/L70. In that cohort, however, CRP level did not add to risk prediction 
among intermediate-risk women. 
 The negative study69, an analysis from the Framingham cohort, 
estimated the 10-year risk for incident cardiovascular disease by tertile of CRP 
level among participants previously stratified as having a 10-year Framingham 
risk score between 10% and 20%. Tertile cut-points were 0.81 mg/L and 3.78 
mg/L. The estimated 10-year risk did not significantly differ among the 3 CRP 
tertiles, and all 3 subgroups based on CRP level had an estimated 10-year risk 
in the intermediate range. 
 The body of evidence that CRP level is independently associated with 
incident CHD is strong, with a risk ratio of 1.58 (CI, 1.37 to 1.83). 
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 The strength of evidence from studies that attempted to measure the 
effect of using CRP level to improve risk classification among persons initially 
classified as intermediate-risk is moderate. Among intermediate-risk persons, 
subgroups with high CRP levels generally had a higher risk for coronary events 
than did those with average or low CRP levels. 
 Recently, these researchers reported a good-quality analysis of 
Framingham data71 in  which they calculated the risk reclassification of 
individual study participants when CRP level was added to traditional risk 
factors; including CRP level improved risk assessment by appropriately 
reclassifying a statistically significant percentage of incident CHD cases and 
noncases into higher or lower risk categories. 
 Although the types of analyses differed, 4 large, good-quality cohort 
studies are consistent in finding that assessing CRP level improves CHD risk 
stratification  43,67,68,70  These consistent findings provide moderately strong 
evidence that adding CRP level to risk models in intermediate-risk patients 
improves the identification of those at higher risk for incident CHD. 
 However, additional research is needed to assess the effect of CRP level 
on risk reclassification of initially intermediate-risk persons and to statistically 
evaluate the calibration of prediction models to observed risk . 
 Establishing the independent predictive ability of a new risk factor is 
necessary but not sufficient for assessing its potential usefulness in screening 
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for CHD risk. Other criteria must be considered, such as the prevalence of the 
factor in the target population, the reliability and cost of the test, potential 
harms of testing, and the effect that treatment for the risk factor has on 
modifying risk. C-reactive protein level favorably satisfies most of these 
criteria. 
 National survey data suggest a prevalence of high CRP level of at least 
20% to 25% among intermediate-risk persons66,72. Inexpensive, precise, high-
sensitivity CRP serum assays are available. Although considerable within-
patient variation among CRP measurements has been reported, the reliability of 
2 or 3 serial measurements is similar to that of a total cholesterol assay. 
 Weight loss, exercise, and smoking cessation can reduce serum CRP 
levels, and lowering CRP levels with statin therapy in patients with acute 
coronary syndrome can lower their risk for recurrent myocardial infarction or 
coronary death. 
 The viability of CRP as a new factor in global risk assessment for 
incident CHD is limited by sparse evidence that directly links therapeutic 
changes in CRP level to primary prevention of CHD events. 
 JUPITER (Justification for the Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin), a good-quality randomized, 
controlled trial of rosuvastatin for primary prevention of cardiovascular events 
in 17 802 men and women with elevated (>2 mg/L) CRP levels, low-density 
  28
lipoprotein cholesterol levels less than 3.4 mmol/L (<130 mg/dL) (median, 2.8 
mmol/L [108 mg/dL]), and no other indication (such as diabetes) for statin 
therapy 73.  
 Current guidelines recommend aggressive therapy only for high-risk 
patients, such as those with a Framingham risk score greater than 20%, 
diabetes, or known cardiovascular disease. Because approximately half of the 
patients in JUPITER had a Framingham risk score greater than 10%, these 
results provide evidence that 1 form of intensive risk reduction - aggressive 
lipid-lowering therapy - produces benefit for a population that includes 
intermediate-risk persons. 
 JUPITER did not evaluate whether intermediate-risk patients who are 
reclassified as high-risk by using CRP level would benefit from treatment 
compared with intermediate-risk patients who are not reclassified. 
 For example, the risk reduction from rosuvastatin therapy may have 
been as great in intermediate-risk participants who had CRP levels closer to the 
population average. The study also did not directly test whether lowering CRP 
levels reduced cardiac risk. 
 Finally, JUPITER did not report rates of coronary events separately for 
low-risk and intermediate-risk persons. 
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 Other issues may influence guideline recommendations and merit 
discussion. Cross-sectional studies have found correlations between CRP level 
and traditional CHD risk factors, but the implications for the use of CRP in 
global risk assessment are not clear. 
 The findings have been interpreted to mean that CRP level may 
represent a different aspect of risk, with complex interrelationships among CRP 
level, traditional risk factors, and CHD. Others conclude that elevated CRP 
level is largely attributable to traditional risk factors, and CRP level “may have 
limited clinical utility as a screening tool” 66. 
 Correlation of CRP level with traditional risk factors does not preclude 
its potential association with CHD. The findings of many studies suggest that 
the degree of correlation between CRP level and traditional risk factors is not 
so great that CRP loses its independent effect. 
 Although this statistical independence does not establish causality, it 
does support the potential use of CRP level as an adjunct in global risk 
assessment, particularly for targeted groups-such as intermediate-risk persons. 
 CRP AND ANGIOGRAPHIC CORRELATION  
 High sensitivity C-reactive protein (CRP) ,a marker of  systemic 
inflammation, has been evaluated as a risk  predictor in subjects without known 
coronary artery disease (CAD ) ,in those at risk of CAD  and in patients with 
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stable angina  ,unstable angina  or acute myocardial infarction(MI). Even small 
elevations of CRP, within or just beyond the “normal” range (determined by 
high sensitivity CRP assay) have been found to strongly predict future 
cardiovascular events in almost all studies. However, these studies have not 
adjusted for plaque burden as assessed by coronary angiography .When 
adjustments for CAD have been made, they generally have been limited to 
adjustment for one -,two-or three-vessel disease  previous studies have shown a 
correlation between CRP and the presence of atherosclerosis. 
 Tataru MC et al 74 showed correlation hs CRP and the severity of 
atherosclerosis in myocardial infarction patients with stable angina pectoris. 
  Zebrack et al, 75 showed hs CRP correlates with extent of coronary 
artery disease, Nyandak et al,76  also showed correlation of hs CRP with extent 
of coronary artery disease. And hs CRP levels have a correlation with the 
disease burden in coronary artery disease patients.  
 Peppes et al, 77 study showed correlation between myocardial enzyme 
serum levels and markers of inflammation with severity of  coronary artery 
disease and Gensini score . 
 Monterio et al, Liu Haihang et al 78 Katrisis et al 79 showed correlation 
of hs CRP with severity of coronary artery disease 
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Study characteristics and adjusted estimates of CHD risk  
Associated with CRP 
Study 
Participants 
n 
Follow up y Men% 
Out 
comes 
Framingha
m Risk 
factors at 
Other 
Adjusted 
covariates 
CRP quantile 
analysed 
Effects size 
(95%CI) 
COHORT STUDIES         
Kflenig et al.,  2005 3971 10 54.3 Major CHD events 7 5 
>3.0 vs <1.0 mg/L 
1.3-3.0 vs. <1.0 mg/L 
1.45 
1.08 
Koenig et al., 2004 3435 6.6 100 Major CHD events 7 0 
>3.0 vs <1.0 mg/L 
1.0-3.0 vs. <1.0 mg/L 
2.21 
1.44 
St. Pierre et al., 2005 1982 13 100 Major CHD events 7 3 
Highest vs Lowest 
Quartile 0.98 
Wilson et al., 2005 4446 8 43.8 Major CHD events 6 0 
>3.0 vs <1.0 mg/L 
1.0-3.0 vs. <1.0 mg/L 
1.22 
1.38 
Park et al, 2002 967 6.4 90.5 Major CHD events 5 3 
1 Unit increase in log 
scale 1.49 
Lowe et al., 2004 3065 7.5 100 Major CHD events 5 1 
Highest vs Lowest 
Quartile 1.72 
Lawlor et al., 2005 2723 3.5 0 CHD events 6 6 Doubling Of CRP Level 1.03 
Mora et al., 2006 27742 9.9 0 CVD events 7 2 Increasing quantiles 
1.22 
1.24 
1.40 
1.68 
Tzoulaki et al, 2007 923 17 67.1 CVD events 6 3 Highest Vc lowest tertile 
1.62 
31 
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Nested Case - Control Studies        
 
Boekholdt et al., 2006 3272 6 64.1/ 63.4 Major CHD events 7 1 Increasing quartiles 
0.87 
1.28 
1.66 
Luc et al., 2003 772 5 100 Major CHD events 7 1 Increasing tertiles 
0.81 
2.16 
Danesh et al., 2004 5933 19.4 72/69 Major CHD events 6 3 
Highest Vc lowest 
tertile 1.37 
Danish et al., 2000 1149 9.5 100 Major CHD events 6 2 
Highest Vc lowest 
tertile 2.61 
Ridker et al., 1997 492 8 100 Major CHD events 5 3 Increasing Quartiles 
1.5 
2.4 
2.6 
Case - Cohort studies         
Pischon et al ., 2007 979 6 75.2/39.5 Major  CHD events 7 0 
>3.0 vs <1.0 mg/L 
1.3-3.0 vs. <1.0 mg/L 
2.56 
1.88 
Koenig et al.,  2006 1058 11 0 Major  CHD events 7 4 
Highest Vc lowest 
tertile 1.35 
 
 
32 
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 A prespecified analysis of the Pravastatin or Atorvastatin Evaluation and 
Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 
22) trial82 revealed similar associations between CRP reduction and risk of 
recurrent coronary events among patients w The Reversal of Atherosclerosis 
with Aggressive Lipid Lowering (REVERSAL) trial83 demonstrated that 
lowering CRP concentrations in patients with coronary disease with intensive 
statin therapy results in reduced atherosclerotic lesion progression with acute 
coronary syndromes Previously, Cholesterol and Recurrent Events trial, which 
had enrolled patients with an MI in the preceding 3 to 20 months, examined the 
association between hs-CRP and coronary events.84 Again, however, an 
increased risk of coronary events became apparent only with hs-CRP levels in 
the top quintile (in this case, >6.6 mg/L), with no evidence for a gradient of risk 
across the lower quintiles. Moreover, the association between CRP levels and 
coronary events was greatly attenuated and no longer significant in patients 
randomized to statin therapy. An association between hs-CRP and 
cardiovascular outcomes has been seen in 2 cohorts of patients with 
angiographically proven coronary artery disease.85 However, both studies 
included a mix of patients with stable and unstable angina, and the latter group 
is known to have acutely elevated levels of CRP and a worse prognosis 
Moreover in one of the studies, only CRP in the top quartile (>12.7 mg/L) was 
a significant predictor of cardiovascular events, and this association was no 
longer apparent in patients taking a statin.  
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CRP AS A SCREENING TEST. GUIDELINES AND 
RECOMMENDATIONS. 
 "How should hs-CRP be measured?" The hs-CRP assay, to reduce 
within-individual variability, should be performed in a metabolically stable 
person without obvious inflammatory or infectious conditions. Results for hs-
CRP should be expressed as mg/L only. Two assays, averaged, fasting or 
nonfasting, and optimally 2 weeks apart, provide a more stable estimate of level 
of this marker. If a level of >10 mg/L is identified, there should be a search 
initiated for an obvious source of infection or inflammation, which could 
obscure any prediction of coronary risk that might be attributed to the elevated 
level. That result of >10 mg/L should then be discarded and the hs-CRP 
measured again in 2 weeks.  
 The cutpoints of low risk (<1.0 mg/L), average risk (1.0 to 3.0 mg/L), 
and high risk (>3.0 mg/L) correspond to approximate tertiles of hs-CRP in the 
adult population. The high-risk tertile has an 2-fold increase in relative risk 
compared with the low-risk tertile. These tertiles are based on distributions of 
hs-CRP samples from >15 populations involving >40 000 persons gathered for 
the purpose of this workshop, allowing adequate definition of the population 
distribution. In general, the high-risk category includes the skewed tail of the 
distribution.  
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CRP AND FUTURE RESEARCH. 
  Despite the statistically significant results of these studies, larger cohorts 
are required in local settings to assess the relationship of hs-CRP levels with 
the severity of coronary atherosclerosis in local settings. The coronary 
angiographic assessment is based upon luminal assessment and lacks plaque 
visualization. Intravascular ultrasound (IVUS) based assessment of coronary 
atherosclerotic burden in correlation with hs-CRP levels may be an area of 
interest for future investigation 
 Finally, the entire adult population should not be screened for hs-CRP 
for purposes of cardiovascular risk assessment. Little evidence supports a 
recommendation for widespread screening for hs-CRP as a public health 
measure (Class III, Level of Evidence C). Such a recommendation would have 
to be based on additional evidence from studies of potential benefits and harm 
for such a screening initiative.81  
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MATERIALS AND METHODS 
  This study included 80 patients undergoing diagnostic coronary 
angiography at the Cardiology Department of Stanley medical college and 
Hospital. CAG was done in the cath lab of the Department of Cardiology, 
Stanley medical college and Hospital.  
Inclusion criteria  
 All patients of IHD admitted for CAG in department of cardiology 
SMCH    
Exclusion criteria 
1. Patient with past CABG 
2. Patient with PTCA 
3. Patient with valvular heart disease. 
4. Patient with hepatic dysfunction. 
5. Patient with a major non-cardiovasculardisease. 
6. Patient with collagen vascular disease. 
7. Any systemic infection. 
8. Patients with history of coronary angiography in the recent past 
9. Unwilling to give consent .  
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 The selected cases were those who had suffered recent Acute Coronary 
Syndrome and those with Chronic CAD .  
 Recent myocardial infarction is defined as an acute episode of infarction 
< 1 months from the time of the investigation.   
 80 cases were selected for inclusion in the study based on clinical 
assessment and laboratory screening. An informed  consent was obtained from 
each patient before inclusion in the study. Patient age , gender ,smoking history 
body mass index, hypertension (systolic and diastolic blood pressures), heart 
rate, and medication history were recorded. Serum concentrations of total 
cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density 
lipoprotein (HDL) cholesterol, glucose and creatinine using standard laboratory 
procedures 
 Hypertension was defined as systolic pressure more than140mmHg or 
diastolic  pressure more than 90 mmHg after multiple measurements in a sitting 
position at rest, or patients already on antihypertensive medication. Diabetes 
mellitus was defined as fasting blood sugar more than 126 mg/d L on two 
occasions, or as patients already on oral hypoglycemic agents or insulin shots. 
Hypercholesterolemia was defined as total cholesterol more than 200 mg/ dL or 
LDL-C more than 130 mg/dL, or as patients already on statin (3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor) treatment. 
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  Blood samples of the participants were sent for analysis of serum hs-
CRP levels.  
Determination of CRP  
 C-reactive protein was quantified by the particle enhanced immuno-
turbidimetric assay. 
 Human CRP agglutinates with latex particles coated with monoclonal 
anti CRP antibodies. The precipitate is determined turbidimetrically, Measuring 
range is between 0.15-20.0 g/dl    
 Patients were divided into three risk groups according to hs-CRP levels 
(< 1 mg/L - low risk ,  1-3 mg/L - average risk and  >3 mg/L- high risk).  
ECHOCARDIOGRAPHIC DATA  
 Two dimensional and M-mode measurements were obtained with 
patients in left lateral position using an Aloka SSD 4000 phased array system 
equipped with Tissue doppler and Harmonic imaging technology with Doppler 
frequency of 2.5 to 3.8 MHz. With measurement of LV end diastolic dimension 
in diastole and LV end systolic dimension in systole, LV Ejection fraction was 
measured. 
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CORONARY ANGIOGRAPHIC DATA  
 Coronary angiogram was done in the Siemens mobile unit cath lab in 
our hospital. Coronary angiography was performed by the Radial approach or 
by femoral approach.  
 Coronary angiograms were done through radial or right femoral 
approach using modified seldinger technique  after getting patient's and 
patient's relative consent and included at least 4 views of the left coronary 
artery and 2 views of the right coronary artery Low osmolar non ionic contrast 
agent (Omnipaque) was used. Coronary artery stenosis was evaluated by use of 
multiple projection quantitative analysis was done with a medical imaging 
system CMS analysis software. 
Determination of CAD severity 
 Following coronary angiogram, the extent and severity of CAD were 
assessed using Gensini score (86,87). The degree of narrowing was assessed by 
taking into account the maximum narrowing of each stenotic lesion in at least 
two orthogonal views.  
 The severity of CAD was evaluated by the 0 to 3 vessel disease score 
and the Gensini score . In the clinical 0 to 3 vessel disease scoring system 
,arteries were as being involved if more than 50 % luminal diameter narrowing 
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occurred, and the patients were defined as having 0-,1-,2-,3-vessel disease 
according to the number of involved vessels.  
 The  Gensini  scoring  system is a valuable aid to estimate the severity 
of CAD according to angiographic findings . The calculation is based on the 
evaluation of number of stenotic segments along with their respective degrees 
of luminal narrowing and localization within the coronary tree.  
 The Gensini score system  yields a qualitative evaluation of coronary 
angiogram , which grades the narrowing of the coronary artery lumen as 1 for  
1 to 25 % narrowing, 2  for 26% to 50%  narrowing, 4 for 51% to 75% 
narrowing,  8 for 76% to 90% narrowing, 16 for 91% to 99% narrowing, and 
32 for total occlusion. This score is then multiplied by a factor that takes into 
account the importance of the lesion position in the coronary arterial tree, e.g., 
5  for the left main coronary artery , 2.5 for the proximal portion left anterior 
descending branch or proximal circumflex artery, 1.5 for the mid LAD region,1 
for the distal left anterior  descending branch, and 1 for the mid-distal region of 
the circumflex artery or the right coronary artery, 0.5 points for second 
diagonal branch or LCX posterolateral  branch. 
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 Schematic drawing of the GENSINI score. The method assigns a 
different severity score depending on the degree of stenosis, its location 
(proximal, middle or distal) along the target vessel and the type of coronary 
vessel involved (LAD, LCX or RCA). MLCA, main left coronary artery; LAD, 
Left anterior descending; LCx, Left circumflex; RCA, Rignt coronary artery. 
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STATISTICAL ANALYSIS 
 Data was analysed using Statistical Package for the Social Science 
(SPSS) Version 11.5 for Windows. Descriptive (frequencies, Percentages, 
Mean and Standard Deviation) and inferential Statistics were used to analyze 
the data. The inferential statistics used included Chi square, analysis of 
Variance, correlation coefficient.  
 Continues variables were presented as mean ± (SD). Continuous 
variables were compared through ANOVA test, Categorical variables by  
chi-square test and correlation Coefficient was done where applicable. For all 
statistical tests P <0.05 was considered as statistically significant.   
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RESULTS AND DATA ANALYSIS 
 The data were collected from a sample of 80 patients. In this chapter 
deals with the analysis and interpretation of data collected. A total of 80 
patients were include in the study. Patients were divided into three groups 
according to their level of CRP. The level of CRP < 1.0 mg/L was consider as 
group I, 1.0 mg/L to 3.0 mg /L group II and > 3.0   mg /L group III. Out of 80 
study subjects, 19 subjects were in Group I, 30 in Group II and 31 subjects 
were in group III,. 
Table-1 
High Sensitive C-reactive Protein (hs-CRP) distribution of  
the study Patients 
 
hs-CRP Number of  Patients Percentage 
GROUP-I (< 1.0 mg / L) 19 23.75 
GROUP –II 
(1.0 – 3.0 mg / L) 
30 37.50 
GROUP-III 
 (> 3.0 mg / L)  
31 38.75 
TOTAL 80 100 
 
 The above shows that distribution of the hs-CPR level among the study 
patients. A total of 80 patients were included in the study.  Patients were 
divided into three groups according to their level of  hs-CRP. Out of 80 patients  
19 ( 23.8) belongs to Group I, 30 ( 37.50 %) was group II and rest 31 (38.75) 
was group III. 
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Table-2 
The distribution of Demographical characteristics of study sample 
Variables GROUP-I 
(N=19) 
GROUP-II 
(N=30) 
GROUP-III 
(N=31) 
TOTAL 
N % N % N % N % 
Sex Male 16 84.20 25 83.30 25 80.60 66 82.50 
Female 3 15.80 5 16.70 6 19.40 14 17.50 
Age 
Mean ±(SD) 
48.74 ±10.84 49.77 ±7.63 55.48 ±7.93 51.74 ± 9.01 
 
 From the above table, a total sample of 80 was used for analysis. Males 
comprised 66 (82.50%) and female 14 (17.50%) of the total, Majority of them 
were males. The mean age of the whole group was 51.74 ± 9.01. Males had a 
lower mean age (51.41± 9.20) when compared to females (53.29 ± 8.21). The 
age group ranged from 28 to 73 years. 
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Table - 3 
Major risk factors status of the study patients 
Variables 
GROUP-I 
(N=19) 
GROUP-
II 
(N=30) 
GROUP-III 
(N=31) 
Chi-square 
N % N % N % P-value Sign. 
Hypertensive 
Normotensive 
12 
07 
63.2 
36.8 
13 
17 
56.7 
43.3 
14 
17 
45.2 
54.8 
1.94 0.38 *
Diabetics 
Non Diabetics 
06 
13 
31.6 
68.4 
13 
17 
43.3 
56.7 
13 
18 
41.9 
58.1 
0.749 0.69 *
Dyslipidemia 
Non 
Dyslipidemia 
05 
14 
26.3 
73.7 
10 
20 
33.3 
66.7 
12 
19 
38.7 
61.3 
0.813 0.67 *
Smoker 
Non Smoker 
05 
14 
26.3 
73.7 
07 
23 
23.3 
76.7 
09 
22 
29.0 
71.0 
0.256 0.88* 
 
 The above table shows distribution of major risk factors among the 
study patients.  
 Hypertension was found in 12 (63.2 %) in group I, 13 (26.7 %) in group 
II and 14 (14.52 %) in group III. The difference is not significant (p > 0.05) 
among the three groups in chi square test. Hypertensive is higher in all the 
groups then the Normotensive.  
  
  46
 Diabetes mellitus was found 6 (31.6 %) in group I, 13 (43.3 %) in group 
II and 13 (41.9 %) in group III. No significant ( p > 0.05) difference was found 
among the three in Chi squre test. Diabetics are less than the Non Diabetics in 
all the groups.  
 Dyslipidemia was found in 5 (26.3 %) in group I, 7 (23.3 %) in group II 
and 09 (29.0 %) in group III. No significant (P >0.05) difference was found 
among three groups in Chi square test. The table stated that Dyslipidemia is 
less than Non Dyslipidemia in all the groups.  Non smokers are high in all the 
groups.  
 Smoking status it was found in 5 (26.3%) in group I, 07 (23.3%) in 
group II and 09 (29.00%) in group III. The difference is not significant  
(p> 0.05) among the three groups in chi square test 
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Table-4 
Base line Clinical Characteristics of the Study Patients 
Variables GROUP-I 
(N=19) 
GROUP-II 
(N=30) 
GROUP-III 
(N=31) 
ANOVA 
F-value Sign. 
Hs-CRP(mg /L) 
Mean ±(SD) 
0.76 ± 0..13 2.51±0.41 6.67±1.46 268.21 P  
< 0.0001 
TC 
Mean ±(SD) 
167.42 ± 30.34 169.80±33.20 180.74±36.97 1.071 0.34 * 
TG 
Mean ±(SD) 
134.63±44.57 155.03±49.86 146.23±36.20 1.087 0.07 * 
HDL 
Mean ±(SD) 
43.11±7.39 40.97±7.65 42.68±7.05 0.627 0.54 * 
LDL 
Mean ±(SD) 
98.74±29.79 99.57±33.17 108.81±33.52 0.823 0.44 * 
BMI 
Mean ±(SD) 
24.58±4.25 23.98±2.90 23.60±3.02 0.516 0.60 * 
 
* Not Significant  
 The above table shows base line clinical characteristics of the sample.  
 Hs-CRP mean level was found in 0.76 ± 0.13 in group I, 2.51 ± 0.41 in 
group II and 6.67 ± 1.46 in group III. The difference is significant (p< 0.0001) 
among the three groups in ANOVA test. hs-CRP  is higher in group III.  
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 TC mean level was found 167.42 ± 30.34 in group I, 169.80±33.20 in 
group II and 180.74 ± 36.97 in group III. The difference is not significant  
(p > 0.05) among the three groups in ANOVA test.  
 TG mean level was found 134.63 ± 44.57 in group I, 155.03 ± 49.86 in 
group II and 146.23 ± 36.20 in group III. The difference is not significant  
(p > 0.05) among the three groups in ANOVA test.  
 HDL mean level was found 43.11 ± 7.39 in group I, 40.97 ± 7.65 in 
group II and 42.68 ± 7.05 in group III. The difference is Not significant  
(p > 0.05) among the three groups in  ANOVA test.  
 LDL mean level was found 98.74 ± 29.79 in group I, 99.57 ± 33.17 in 
group II and 108.81 ± 33.52 in group III. The difference is not significant  
(p > 0.05) among the three groups in ANOVA test.  
 BMI mean level was found 24.58 ± 4.25 in group I, 23.98 ± 2.90 in 
group II and 23.60 ± 3.02 in group III. The difference is not significant  
(p > 0.05) among the three groups in ANOVA test.  
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Table - 5 
SEX VERSUS MEAN CRP LEVEL 
Hs-CRP 
MALE 
(N=66) 
FEMALE 
(N=14) 
Mean 3.65 3.97 
S Deviation 2.59 2.97 
t-value 0.40 
Significant  0.68 ( Not Significant ) 
 
 This table shows mean hs CRP levels between male and female. Mean 
hs CRP level is slightly higher in female patients than in male patients. but the 
difference is statistically not significant.  
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Table-6 
Distribution of mean vessel and stenosis score 
Variables 
Group-I 
(N=19) 
Group-II 
(N=30) 
Group-III 
(N=31) 
Significant 
ANOVA 
F-value Sign. 
Vessel Score 
Mean ±(SD) 
0.37 ± 0.83 1.40 ± 0.81 2.45± 0.85 37.84 P < 0.001
 Stenosis 
Score 
Mean ±(SD) 
4.00 ± 6.74 17.67 ± 11.40 45.13 ± 23.33 42.47 P < 0.001
 
 The above table showing the distribution of mean vessel and Stenosis 
Score between the three hs CRP groups of patients. The mean vessel score was 
0.37 ± 0.83, 1.40 ± 0.81 and 2.45 ± 0.85 in group I, group II and group III 
respectively. F-Values reveals that mean score difference were statistically 
significant (P<0.05) among the three groups in ANOVA Test.  
 The mean Stenosis score was 4.00 ± 6.74 , 17.67 ± 11.40 and 45.13 ± 
23.33 in group I, group II and group III respectively. The score difference were 
statistically significant (P <0.05) among the three groups in ANOVA Test.  
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Table-7 
Correlation between hs-CRP score with Stenosis score and Vessel score 
Variables Stenosis Score Vessel Score 
hs-CRP  level 0.760 ** 0.697** 
 
** Correlation is significant at P < 0.01 
 
 Significant correlation were found between hs-CRP and vessel Score. 
The scatter diagram shows that correlation coefficient was 0.760 which is 
highly significant  (P < 0.01). Therefore there was linear positive correlation 
between hs-CRP and stenosis Score.  
 Significant correlation were found between hs-CRP and vessel Score. 
The scatter diagram shows that correlation coefficient was 0.697 which is 
highly significant (P < 0.01). Therefore there was linear positive correlation 
between hs-CRP and vessel Score .  
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Table-8 
Distribution of  patients by Vessel Scores 
Vessel 
Score 
Group-I 
(N=19) 
Group-II 
(N=30) 
Group-III 
(N=31) 
Total 
(N=80) 
N % N % N % N % 
0 15 78.9 3 10.0 1 3.2 19 23.8 
1 2 10.5 15 50.0 4 12.9 21 26.3 
2 1 5.3 9 30.0 6 19.4 16 20.0 
3 1 5.3 3 10 20 64.5 24 30.0 
Total 19 100 30 100 31 100 80 100 
 
 This table shows distribution of patients by vessel score in CRP groups. 
In group I, 15 patients  (78.9%) had 0 vessel score, 2 patients (10.5 %) had 1 
vessel score,1 patient each with vessel score of 2 and 3 (5.3 %). In group II, 3 
patients had 0 vessel score (10 %), 15 patients had 1 vessel involvement (50%), 
9 patients had 2 vessel involvement (30%), 3 patients had 3 vessel involvement 
(10 %). In group III, 1 patient had 1 vessel involvement (3.2 %), 4 patients had 
1 vessel involvement (12.9%), 6 patients had 2 vessel involvement (19.4 %), 
and 20 patients had 3 vessel involvement (64.5 %). Increased hs CRP level  
associated with increased vessel score .  
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Table-9 
hs-CRP  Group with Diagnosis 
 Group-I 
(N=19) 
Group-II 
(N=30) 
Group-III 
(N=31) 
Total 
(N=80) 
N % N % N % N % 
MI 9 47.4 18 60.0 17 54.8 44 55.0 
UA/NSTEMI 4 21.1 4 13.3 4 12.9 12 15.0 
CSA 6 25.0 8 26.7 10 32.3 24 30.0 
 
 This table shows patient population in CRP groups. In group I,  
9 patients had myocardial infarction. 4 patients had UA/NSTEMI.  6 patients 
had CSA. In group II 18 patients had myocardial infarction,4 patients had 
UA/NSTEMI, 8 patients had CSA. In group III, 17 patients had myocardial 
infarction, 4 patients had UA/NSTEMI, 10 patients had CSA. Myocardial 
infarction patients were common in all the three groups. 
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Table-10 
hs-CRP  Group with  vessel involvement. 
 Variables Group-I 
(N=19) 
Group-II 
(N=30) 
Group-III 
(N=31) 
Total 
(N=80) 
N % N % N % N % 
Left Main - - - - 5 16.13 05 06.25
LAD 3 15.79 21 70.00 29 93.55 53 66.25
LCX 3 15.79 12 40.00 20 64.52 35 43.75
RCA 1 05.26 11 36.67 22 70.97 34 42.50
 
 This table shows the distribution of vessel involvement in three Hs CRP 
groups. left main involvement was seen in 5 patients .All 5 patients  were in 
group III. Left anterior descending artery is the most commonly involved 
vessel in all three groups. Followed by circumflex and Right coronary artery. 
Table-11 
Hs-CRP  levels with Diagnosis 
Variables MI UA/NSTEMI CSA 
Significant 
ANOVA 
F-value Sign. 
Mean 3.99 3.62 3.24 0.631 0.54* 
Sd 2.75 2.96 2.64 
 
* Not Significant 
 This table shows mean hs CRP levels in three groups of patients. Mean 
hs CRP of 3.99 was seen in patients with previous myocardial infarction, 3.62 
in patients who had UA/NSTEMI and  in patients with chronic stable angina.   
  55
Table12 
Mean EF with diagnosis. 
Variables 
MI 
(N=44) 
UA/NSTEMI 
(N=12) 
CSA 
(N=24) 
Significant 
ANOVA 
F-value Sign. 
E-F 44.48 ± 3.78 57.42 ± 2.87 58.04± 3.22 144.35 P < 0.001
 
 This table shows mean Ejection fraction in different diagnostic groups 
of patients. Mean ejection fraction was lower in previous myocardial infarction   
 
Table-13 
 Correlation between hs-CRP score  with EF  
Variables E F 
hs-CRP Score -0.043 
 
The poor inverse correlation between hs-CRP level  and E-F where found in 
our study. 
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DISCUSSION 
 Several population based studies have revealed that high sensitive  
C-reactive protein (hs-CRP) is an exquisitely sensitive systemic marker of 
inflammation and a powerful predictive marker of future cardiovascular risk, 
Ample data supports that CRP levels are elevated in patients with clinical CAD 
identified by angiography. 
 The mechanisms responsible for the association between CRP and 
cardiovascular disease are not clear. CRP may be only a marker of 
inflammation and thrombotic risk, without any specific role in the degree of 
atherosclerosis8,9 or it may have a direct effect. The following observations 
suggest that there may be a direct effect: i) CRP has been found in 
atherosclerotic lesions, ii) CRP binds to low density lipoprotein (LDL), 
allowing LDL to be taken up by macrophages without the need for 
modification,7 and iii) Administration of CRP promotes inflammation in 
humans and atherosclerosis in an animal model.10,11 
 Various studies have found that CRP is a determining factor in plaque 
rupture,12-13 prognosis after non-ST elevation MI,56 recurrent in-hospital cardiac 
event, long term mortality after MI,58 and recurrent ischemic event after 
coronary artery bypass grafting.52 Also, among patients with known stable 
coronary disease, a strong positive correlation between CRP measured at 
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baseline and future acute coronary events has been demonstrated in most 
studies.35-37  
 A statement from the Centers for Disease Control and Prevention and 
the American Heart Association (CDC/AHA) reached the following 
conclusions for the use of serum hs-CRP to estimate cardiovascular risk:30 i) 
The average of two assays, fasting or non-fasting, and optimally obtained two 
weeks apart provide a more stable estimate than a single measurement, ii) For 
the determination of cardiovascular risk, low, average, and high risk values 
were defined as <1, 1 to 3, and >3 mg/L; these values correspond to 
approximate tertiles in the general population. It was suggested that a value 
above 10 mg/L should initiate a search for a source of infection or 
inflammation. The measurement of hs-CRP should be repeated in two weeks 
and iii) Among patients with known coronary heart disease (CHD), it was 
suggested that a value >3 mg/L is appropriate for predicting outcomes in 
patients with stable CHD. 
 In a large study using the above recommendations from the CDC/AHA, 
3771 patients with stable coronary artery disease in the PEACE trial were 
evaluated.31 Patients had hs-CRP measured at baseline and were followed for 
outcomes of cardiovascular death, MI or stroke over a mean follow-up of 4.8 
years. The following findings were noted: i) Across all measured subgroups, 
including men and women, patients on or off statin therapy, and patients with 
or without prior coronary revascularization, higher baseline hs-CRP levels were 
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associated with significantly a higher rate of cardiovascular events compared to 
those with hs-CRP <1 mg/L (hs-CRP 1 to 3 mg/L: adjusted hazard ratio [HR] 
1.39, 95% CI 1.06-1.81; hs-CRP >3 mg/L: adjusted HR 1.52; 95% CI 1.15-
2.02) and ii) An elevated hs-CRP was predictive of the development of heart 
failure and new diabetes.  In addition, serum CRP may predict coronary disease 
progression and coronary disease with inducible ischemia on stress testing. 
 Despite abundant studies, there is still a debate in scientific societies 
whether inflammation is a chronic process leading to atherosclerosis or it is an 
acute response to plaque rupture, the main pathogenic event in acute coronary 
syndrome. In this context this present study was designed to evaluate the role 
of CRP in prediction of degree of coronary stenosis in patients with chronic 
stable angina and acute coronary syndromes, compared CRP to other 
established CHD risk factors to see whether it has an independent role after 
adjustment for other risk factors. 
 In our study we also observed that CRP levels did not vary much with 
history of smoking, though many studies revealed smoking increases CRP 
levels, we could not either confirm this or disprove this, based on our data. 
 In this study, it is revealed that CRP levels >1 mg   is an independent 
predictor of stenotic lesions after adjustment for other risk factors. 
 Zebrak et al57 also found c reactive protein corrrelates with extent of 
coronary artery disease. Accordingly, our study revealed majority of our 
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patients with multi vessel disease had higher CRP levels added to that, only 
few patients with single disease had higher CRP levels. 
 Besides the degree of stenosis, the Gensini scoring system gives ample  
weightage to the proximity of lesions within the coronary tree, the lesions in  
left main  coronary artery getting  the maximum score. The overall score thus  
reflects not only the product of number of  lesions with their respective  
degrees of stenosis, but also the functional significance of lesions in terms of  
the area of myocardium at stake.  
 This study also showed reasonable variation in mean hs-CRP levels 
according to the severity of Coronary atherosclerosis as assessed by the 
Gensini score angiographic stenosis score was found to be higher in patients 
with higher hs-CRP levels (Table 6). This shows that hs-CRP level also has 
correlation  with the disease burden apart from being a well known indicator of 
presence of Acute coronary syndrome.  
 Nyandak et al,76 observed in their studies correlation between hs CRP 
levels and angiographic severity  and also studies by  Hansat et al89  observed 
correlation between extent of coronary artery disease and hs-CRP levels which 
are consistent with our present study. 
 It therefore suggests    that inflammation is not only an important trigger  
mechanism of  acute coronary syndrome related to plaque rupture, but also a  
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promoter of chronic  atherosclerosis, as proposed that CRP might play an  
atherogenic role through an interaction with low density lipoproteins.  
 Elevated CRP levels were correlated with the complexity of coronary 
artery  lesions by Moukarbel et al90 who found elevated CRP levels in 56%, 
84% and 93%  of cases with low, intermediate and highly complex coronary  
lesion groups respectively.  In our study elevated CRP levels ( > 1mg)  were 
observed in patients with  more stenosis scores. Moreover patients with CRP 
levels < 1 mg only rarely had  higher stenosis score. 
 There have also been attempts to link serum hs-CRP  levels to the 
vulnerability of coronary plaques in terms of plaque ulceration and 
inflammation.  
  Espligureal R et al91 reported significantly higher hs-CRP levels in  
patients with acute coronary syndrome compared to chronic stable angina. 
Evidences like this emphasize the importance of plaque morphologies in 
addition to the extent of coronary atherosclerosis.  
 The issue was addressed recently in the study by Peppes et al77 in which 
significant positive correlations were found between angiographic findings, 
extent of myocardial damage and serum levels of myocardial enzyme and 
inflammatory biomarkers. 
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 Higher hs-CRP levels were associated with higher stenosis score in  
CAD patients, which are consistent with the present study results.  Hence, hs-
CRP is a single cardiovascular risk factor and increases in  CRP concentration 
within  reference  limit are associated with future cardiovascular events. 
Furthermore elevated level of C reactive protein can predict the coronary 
atherosclerotic disease burden.  
 Limitations:  Despite the statistically significant results of this study, 
larger cohorts are required in local settings to assess the relationship of hs-CRP 
levels with the severity of coronary atherosclerosis in local settings. 
 The coronary angiographic assessment is based upon luminal 
assessment and lacks plaque visualization. Intravascular ultrasound (IVUS) 
based assessment of coronary atherosclerotic burden in correlation with hs-
CRP levels may be an area of interest for future investigation. 
 
. 
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CONCLUSION 
• CRP levels were elevated in our study group irrespective of other 
traditional risk factors in Acute coronary syndromes. 
• Gensini scoring of CAD angiographic severity is in linear correlation to 
mean CRP levels.  
• CRP Levels is correlating well with angiographic stenosis severity. 
• Low CRP (<1 mg) is associated with less severe stenotic lesions. 
• High CRP (>3 mg )is associated with severe stenotic lesions. 
• Number of vessels involved in CAD patients correlates directly with 
CRP level groupings.  
• Higher the CRP levels, more vessels involved.  
• Those with Low CRP (<1 mg), had single vessel disease. 
• Those with left main disease and its equivalents, triple vessel disease 
had very high mean CRP levels. 
• It appears that ejection fraction did not predict CRP elevation. 
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PROFORMA 
Name  :      IP NO : 
Age  :      D.O.A. :  
Sex  :     D.O.D. : 
Address : 
Admission Diagnosis : UA / NSTEMI 
    STEMI – AW / IW  
Thrombolysis : Given / Not   (Time interval – 
Killip Class on admission :  
Presenting complaints and duration : 
Chest Pain : 
Dyspnea : 
Palpitations : 
Other Symptoms : 
Past History : 
       Diabetes mellitus / Systemic Hypertension / CKD / PVD / Stroke / Prior 
MI 
Personal History : 
 Smoking / alcoholic   
 
Clinical examination : 
Height :  Weight :  BMI : 
Vitals :-    Pulse : BP : 
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CVS Examination    : 
RS Examination    : 
Other systems  examination  : 
 
INVESTIGATIONS 
 
 
1.  Hb, TC, DC, ESR, PLATELET COUNT  
 
 
2.   BLOOD SUGAR -  F  / PP / R –  
 
      BLOOD  UREA   
 
3.  SERUM CREATININE 
 
4.    SERUM ELECTROLYTES 
 
 
5.   CARDIAC ENZYMES 
 
 
5.  LIPID PROFILE –  
 
6 . hs-CRP 
 
6. ECG 
 
7.  ECHO 
 
8.  CAG  
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NAME :             Age:                                   MRD No:    
 
 
D.O.P:                                                                   CD No    :   
     
                                   Cath No :    
 
       Angio No:   
 
Unit:                                                                      DONE BY:  
 
Pre cath Diagnosis:  
 
CAG Procedure :                                           Hemodynamic Parameters 
 
 
 Artery Used :    Aortic Systolic:  
 
 Technique :                        Diastolic: 
 
 Catheters used:  
 
 Dye Used        : 
 
PROCEDURE: 
 
 
REPORT: 
 
LMCA  :     
 
LAD   :    
 
LCX   :    
 
RCA   :   
 
IMPRESSION   :  
 
ADVICE  :                                                                                    
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GLOSSARY 
 
CAD   :  Coronary Artery disease 
 hs CRP :  High sensitive C Reactive protein 
DM   :  Diabetes Mellitus 
BMI   : Body mass index 
ECG   :  Electro cardio Gram 
LMS   :  Left Main Stenosis 
MI   :  Myocardial Infarction 
CVD   :  Cardio Vascular Disease 
LDL   :  Low Density Lipoprotein 
HDL  :  High density lipoprotein 
LVEF  :  Left Ventricular Ejection Fraction 
LVEDV  :  Left Ventricular End Diastolic Volume 
LVESV  :  Left Ventricular End Systolic Volume 
LVEDD  :  Left Ventricular End Diastolic Dimension 
LVESD  :  Left Ventricular End Systolic Dimension 
LMCA  : Left Main Coronary Artery 
LAD   :  Left Anterior Descending Artery 
LCX   :  Left Circumflex Artery 
RCA   :  Right Coronary Artery 
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1 59 M 208773 MI Yes NO Yes NO 210 137 33 146 167 65 23.30 48 5.80 0 P80                       P80                          D30,PDA90                3 50
2 58 F 206304 MI NO NO NO NO 170 134 48 82 151 55 24.10 52 8.37 0 p99                       p70                          0 2 50
3 55 M 209303 MI NO NO NO NO 113 73 44 54 150 48 21.30 46 0.76 0 0 0 0 0 0
4 72 F 208813 MI Yes Yes NO NO 140 180 36 80 171 69 23.60 42 9.08 D30  p80                       m99                         p60,m99                    3 66
5 46 F 208776 UA /NSTEM NO NO NO NO 162 134 48 91 148 55 25.10 55 0.74 0 0 0 0 0 0
6 54 M 208797 MI NO Yes NO NO 184 150 47 103 166 50 18.00 42 7.20 0 p90                       p40                          0 1 27
7 38 M 208813 MI NO NO NO NO 182 137 40 98 166 50 18.10 48 0.63 0 p50                       p50                          0 2 10
8 49 F 208798 UA /NSTEM Yes NO NO NO 138 202 39 62 150 48 21.00 58 2.68 0 p70                       0 0 1 18
9 55 M 208820 CSA Yes NO NO NO 181 135 44 113 151 65 28.50 58 4.80 0 0 0 0 0 0
10 73 M 211085 CSA Yes Yes NO NO 180 146 42 90 156 65 26.70 55 0.79 0 0 p70,d70                  0 1 14
11 50 F 211121 CSA Yes Yes Yes NO 224 148 59 150 164 69 25.70 55 2.70 0 m70                      m70                         p99                            3 26
12 54 F 211282 CSA Yes Yes Yes NO 170 212 38 82 172 74 25.00 55 2.50 0 p70                       0 m70                            2 18
13 65 M 126280 MI NO NO Yes NO 202 213 40 136 156 65 26.70 44 7.84 0 p90                       d99                          m99,d30                    3 60
14 45 M 211294 MI NO NO NO Yes 180 146 42 90 156 65 26.70 46 2.84 0 p70,m70              0 m99                            2 32
15 62 M 211206 CSA Yes Yes Yes NO 194 137 33 146 166 50 18.10 60 5.20 0 p70                       m70                         d99                            3 30
16 41 M 209826 UA /NSTEM NO NO NO Yes 194 137 40 126 166 50 18.00 60 6.32 0 m99                      0 0 1 24
17 55 F 122851 CSA Yes NO NO NO 150 148 45 76 153 80 34.20 60 0.63 0 0 0 0 0 0
18 40 M 208806 MI NO NO NO Yes 166 123 50 91 170 72 24.90 42 0.82 0 0 0 m20                            0 1
19 47 M 208816 MI NO Yes NO NO 105 130 39 46 156 65 26.70 46 2.56 0 p30                       0 m60.m70                   1 14
20 43 M 208805 MI NO Yes NO NO 123 105 40 62 171 69 23.60 37 2.80 0 p30                       0 0 0 5
21 28 M 208823 MI NO NO NO NO 140 94 44 75 164 69 25.70 50 0.93 0 0 0 p20,m40                    0 3
22 61 M 211463 CSA Yes NO NO NO 127 73 40 75 164 69 25.70 56 2.20 0 m70                      om1 40                   0 1 8
23 50 M 211534 CSA NO NO Yes NO 184 82 33 135 160 65 25.40 55 0.94 0 0 0 0 0 0
24 48 M 211732 CSA NO NO NO NO 140 180 25 80 171 69 23.60 65 2.60 0 0 m90                         m70,d99                    2 28
25 46 M 211508 MI NO NO NO NO 180 146 42 90 156 65 26.70 50 8.82 0 m100                    om1‐90                   p100                           3 88
26 58 M 208834 MI Yes NO NO Yes 124 105 40 63 164 69 25.70 50 5.83 0 m50,d1‐70           m30                         p40                            2 12
27 48 M 208837 MI NO NO NO Yes 115 79 41 59 164 69 25.70 50 6.12 0 m70                      p99                          p70,m50                    3 52
28 64 M 208836 MI NO NO NO NO 150 148 45 76 167 66 23.70 38 5.43 0 M70,                     D70                          0 2 10
29 48 F 199367 CSA Yes Yes Yes NO 240 134 48 168 151 55 24.10 60 3.96 0 M90,D1 90,D299OM1 70,M90         M70,D99                   3 28
30 51 M 208848 MI NO Yes NO NO 170 148 38 82 172 74 25.00 47 3.00 0 0 D90                         M90,D99                   2 32
31 48 M 208824 MI NO Yes Yes NO 249 264 49 147 166 50 18.10 44 2.76 0 P30                       M50,OM1 70         P30,D50                     2 15
32 46 M 208838 MI Yes NO Yes Yes 213 118 39 150 156 65 26.70 47 2.40 0 0 0 D50,70                       1 4
33 58 M 212334 UA /NSTEM Yes Yes NO NO 138 123 35 81 170 72 24.90 55 7.20 0 M40,70                P30,OM1 50          P40,M95                    3 31
34 61 M 212077 UA /NSTEM NO NO NO Yes 151 147 42 88 153 71 30.70 55 2.76 0 P70                       P70,M70,D50        P70                            3 28
35 63 M 208873 CSA Yes NO Yes Yes 246 258 30 165 178 63 19.90 60 1.50 0 M 90                     OM2 99                  0 2 28
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36 65 M 212066 CSA Yes NO Yes NO 194 137 33 146 168 60 21.30 55 6.24 D30  M 40                     OM1 30                  P 99,M99D99            3 47
37 66 M 208847 MI NO NO NO NO 161 148 48 83 165 58 21.30 42 0.92 0 m30                      0 0 0 3
38 60 M 208857 MI NO Yes NO NO 194 137 33 146 172 70 23.70 48 2.35 0 M 50,D 30            0 0 1 5
39 65 M 212795 CSA NO NO NO NO 164 148 41 93 170 68 23.50 60 3.95 0 M90,D70             M99                         P99,M100                  3 64
40 61 M 208864 MI NO NO NO Yes 173 128 42 105 176 66 21.30 44 9.00 D50  P 50,M 70            0 P50,M100                  3 55
41 54 M 211581 CSA Yes Yes NO NO 155 115 43 99 156 68 27.90 55 0.50 0 0 0 0 0 0
42 53 F 208867 UA /NSTEM Yes NO NO NO 182 139 42 112 150 48 21.30 55 7.95 D30  P50                       P 90                         M99                            3 51
43 39 M 208878 MI NO NO Yes Yes 278 87 42 118 184 67 19.70 40 5.62 0 100% MID            0 0 1 48
44 62 M 208886 MI NO NO NO NO 188 130 48 107 172 74 25.00 43 2.38 0 95 ,70 D               0 0 1 28
45 48 M 208880 UA /NSTEM NO NO NO NO 161 148 40 91 168 56 19.80 57 0.86 0 0 0 P 30                           0 2
46 57 M 213083 CSA NO NO NO NO 152 79 54 82 153 71 30.70 55 5.80 D50  90P,99M              P50,D90                  M90                            3 70
47 50 M 177807 MI NO NO NO NO 142 130 36 101 167 53 19.00 42 2.38 0 M70                      P90,                         0 2 26
48 38 M 94221 CSA NO NO NO NO 180 146 42 90 174 72 23.80 55 1.72 0 M99                      0 M50                            2 26
49 40 M 208933 MI Yes NO Yes Yes 205 182 32 137 164 69 25.70 43 0.71 0 M70                      0 0 1 6
50 38 M 208933 MI NO NO NO Yes 140 180 41 80 171 69 23.60 47 1.80 0 0 0 0 0 0
51 43 M 208897 MI NO Yes NO NO 124 105 40 63 164 69 25.70 47 2.65 0 M 50                     P30                          0 1 8
52 40 M 213476 MI Yes Yes Yes Yes 170 212 38 82 166 82 29.80 47 3.00 0 P99                       0 0 1 24
53 41 F 208896 MI Yes Yes Yes NO 222 164 36 153 153 80 34.20 40 0.94 0 0 P30                          0 0 5
54 40 M 208916 MI NO NO NO NO 145 56 64 70 158 64 25.60 43 0.61 0 M30                      0 0 0 3
55 55 M 212667 MI Yes Yes NO Yes 177 143 48 103 176 70 22.60 44 9.02 0 M60                      M100                      M60,D90                   3 50
56 53 M 212912 UA /NSTEM Yes Yes Yes NO 194 137 36 144 168 72 25.50 55 2.40 0 M70                      M90%                     M90                            3 29
57 51 M 213612 MI NO NO Yes Yes 201 109 46 143 174 60 19.80 38 2.90 0 M70                      0 0 1 6
58 47 M 213486 MI Yes NO Yes Yes 202 67 39 150 160 52 20.30 48 7.03 0 M100,D1 100      OM1 70                  P50,D80                     3 94
59 48 M 123125 UA /NSTEM Yes Yes Yes NO 211 177 53 123 165 64 23.50 55 8.24 0 P70                       P90,                         D 99                           3 38
60 47 M 208907 UA /NSTEM Yes NO NO NO 127 156 40 61 167 65 23.30 60 0.80 0 0 0 0 0 0
61 37 M 213475 MI NO NO NO NO 150 148 45 76 167 66 23.70 40 2.28 0 P90                       0 0 1 20
62 60 M 214219 CSA Yes Yes Yes Yes 245 131 39 196 162 69 26.30 55 5.97 0 P100                     0 P70                            2 84
63 60 M 210402 CSA Yes Yes NO NO 140 180 25 80 152 47 20.30 58 6.43 0 P90                       0 M70                            2 24
64 42 M 213860 MI Yes Yes Yes NO 140 180 25 80 168 72 25.50 44 2.77 0 P 70                      0 0 1 10
65 45 M 213857 MI NO NO NO NO 185 122 49 112 164 62 23.10 50 2.75 0 0 M50                         L                              1 2
66 46 M 213430 UA /NSTEM Yes NO Yes NO 201 256 55 95 158 58 23.20 62 2.85 0 D140                     D 90                         0 1 10
67 58 F 212984 CSA Yes Yes NO NO 137 180 48 105 150 48 21.30 58 1.60 0 0 0 0 0 0
68 49 M 213867 MI NO Yes NO NO 195 138 35 125 164 68 25.30 40 3.00 0 P70                       0 0 1 10
69 56 M 214213 MI NO NO NO NO 141 102 40 87 165 58 21.30 38 0.75 0 0 0 0 0 0
70 60 F 213284 MI NO NO NO NO 195 148 42 111 147 45 20.80 42 2.83 0 P 99%                   0 0 1 40
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71 50 M 213120 CSA Yes Yes Yes Yes 214 151 52 132 173 62 20.70 58 0.85 0 0 M30                         0 0 2
72 55 M 213708 CSA Yes NO NO NO 122 62 50 48 160 57 22.30 62 2.30 0 P 90                      P70,OM170           P 30                           2 30
73 55 M 211859 CSA Yes Yes NO NO 154 148 48 91 164 69 25.70 62 6.25 0 M90,D70             M99                         P99,M100                  3 64
74 60 M 213894 UA /NSTEM Yes Yes Yes NO 214 258 36 155 158 57 22.80 62 0.66 0 P50,M70D90       D70,OM3 70          M50                            3 27
75 63 M 211647 CSA Yes Yes Yes NO 201 256 55 95 169 67 23.50 65 7.66 0 P70,M70              OM370                   M99                            3 34
76 52 M 213900 MI NO NO Yes Yes 211 234 49 156 164 69 25.70 43 7.64 0 P90                       M100                      M70                            3 56
77 50 M 213885 MI NO NO NO NO 124 105 40 63 164 69 25.70 46 6.52 0 P99                       OM3 50                  0 2 41
78 60 F 213853 MI Yes Yes NO NO 172 165 46 96 170 72 24.90 46 7.10 0 M50                      M50                        M 100                         3 41
79 42 F 213902 MI NO Yes Yes NO 201 256 55 95 151 55 24.20 43 4.50 0 P 70                      0 0 1 10
80 39 M 213933 CSA NO Yes NO Yes 159 141 42 98 172 68 23.00 56 0.57 0 0 0 0 0 0
